Tolerability of baicalein chewable tablets in chinese healthy volunteers: a single-dose dose-escalating study / 中国药学杂志

ABSTRACT

OBJECTIVE: To evaluate the safety and tolerability of baicalein chewable tablets and establish the maximum tolerated dose in healthy volunteers. METHODS: A randomized, double-blind, dose-escalating, single-center, phase I clinical trial was conducted in 70 healthy male and female subjects. Each subject received oral baicalein only once. Adverse events were identified either by subject self-reporting or evaluation based upon vital signs, physical examination and laboratory parameters. The study was conducted from low to high dose, and the dose escalation was performed only after the safety and tolerability were confirmed favorable. RESULTS: Baicalein chewable tablets were well tolerated and had an acceptable safety profile up to the highest dose of 2800 mg. The vital signs of all subjects were stable, and no QTc interval prolongation was observed during the trial. A total of 11 mild adverse events were reported in 8 subjects. There were no severe adverse events in the study, and none of the adverse events led to withdrawal. CONCLUSION: This study suggests that the innovative drug baicalein chewable tablets are well tolerated in healthy Chinese volunteers within the dose range of 100 to 2800 mg.